IRM's are very unpredictable and result in non-specific immune responses toward antigens and rogue cells that are not well defined nor well understood which can lead to catastrophic events occurring in certain segments of the patient population. Imiquimod is one such small-molecule IRM that causes over a dozen cytokines to be induced by their respective origin of production during their physical contacts with molecules of this drug. During treatments, the users cannot separate themselves from the physiological influences of the ongoing, out of sync, induction of this family of cascading cytokines being induced at unknown and unregulated levels within their bodies during each patient applied application of the drug. As with injection or IV chemo treatments where body weight and rate of drug deterioration after injection is factored into safety profiles for the individual patient, IRM's such as imiquimod do not possess this safety feature and are actually causing unknown or "free-wheeling" pharmacological effects within each user that are increasing the levels of cytokines during the weeks of treatments rather than systematically reducing them over time as we see in traditional chemotherapies. Drug induced autoimmunity is the number one possibility surrounding these IRM's.